- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03661125
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis (SCRIPT)
A Randomised, Balanced, Double-blind Two-way Crossover Design Study to Evaluate the Effects of SRC Kinase Inhibitor, Saracatinib, on Brain Activity Associated With Visual Processing in Patients With Parkinson's Disease Psychosis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Miriam Vignando
- Phone Number: +44 (0) 7492634351
- Email: miriam.vignando@kcl.ac.uk
Study Contact Backup
- Name: Sonali Dave
- Phone Number: 07906990964
- Email: sonali.dave@kcl.ac.uk
Study Locations
-
-
Camberwell
-
London, Camberwell, United Kingdom, SE5 8AF
- Recruiting
- Mitul Mehta
-
Contact:
- Mitul Mehta
- Phone Number: +44 (0)2032283053
- Email: mitul.mehta@kcl.ac.uk
-
Contact:
- Miriam Vignando
- Phone Number: 07492634351
- Email: miriam.vignando@kcl.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Understand the study procedures and agree to participate by providing written informed consent.
- Have a confirmed diagnosis of Parkinson's disease using internationally accepted UK brain bank criteria.
- Be male or female
- Be right handed
- Aged 40 years or over
- Be judged to be in good health by the investigator, based on clinical evaluations including laboratory safety tests, medical history, physical examination, 12 lead ECG and vital signs measurements performed at screening and prior to administration of the initial dose of study drug.
- Have a score of at least 22 on the Montreal Cognitive Assessment (MoCA).
- Have a diagnosis of idiopathic PD with moderate severity
- Have a combined score of at least 6 or an individual score of at least 4 on the neuropsychiatric inventory (NPI [20]) 23 items A (delusions) and/or B (hallucinations).
Exclusion Criteria:
- Is a female of child bearing potential
- Is currently taking anticholinergic medication
- Is currently taking any medication known to be a moderate or potent CYP3A4 inducer or inhibitor.
- Has an ongoing disability, medical or neurological history, cognitive impairment, or conditions that in the opinion of the investigator may interfere with study conduct or clinical assessments.
- Refuses to be withdrawn from quetiapine (see section 4.7).
- Has a family history of psychosis in a first degree relative
- Has poor peripheral arterial/venous access or recent wrist trauma that will restrict ability to gain venous access.
- Is currently using prescription or non-prescription drugs and herbal supplements, which are deemed to affect the integrity of the study, within 7 days or 5 half-lives (whichever is longer) prior to the first dose of trial medication. As an exception, paracetamol or acetaminophen may be used at doses of 1 g/day.
- Has a history of sensitivity to any of the study medications or any of the excipient constituents.
- Has a history of febrile illness within 5 days prior to the first dose
- Has a hairstyle which would affect EEG recording.
- Has any condition possibly affecting drug absorption (eg, gastrectomy).
- Has a history of regular alcohol consumption exceeding 14 units/week (6 glasses of 13.0% wine (175ml), 6 pints of 4.0% lager or ale (568ml), 5 pints of 4.5% cider (568 ml) or 14 glasses of 10.0% spirits (25ml)) within 6 months of screening.
- Uses tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
- Uses caffeine containing products of the equivalence of 5 cups of regular filter coffee per day
- Has a positive urine drug screen on or after the screening visit during their active involvement in the study for opiates, methadone, cocaine, amphetamines (including MDMA), barbiturates, benzodiazepines and cannabinoids.
- Is unwilling or unable to comply with the Lifestyle guidelines.
- Has, in the opinion of the investigator, has any medical or psychological condition or social circumstances which would impair their ability to participate reliably in the study, or who may increase the risk to themselves or others by participating.
- Is male and is unwilling to follow the contraception guidance or has a female partner of child bearing potential who is unwilling to follow the contraception guidance throughout the study.
- Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN)
- Total bilirubin > 1.25 x ULN
- Known congenital long QT syndrome
- Baseline resting QTcF > 470ms on 12 lead ECG
- Positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody at screening
- Known to have tested positive for human immunodeficiency virus.
- Participation in another clinical study with an investigational product administered in the last 3 months
- Below the lower limit of normal Hb, total WBC and neutrophils on blood counts as per the reference ranges of the laboratory conducting the tests.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Saracatinib or placebo
In the first arm of the study, participants will be randomised into either the group that receives Saracatinib (study drug) or the Placebo.
|
AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49.
Two tablets to be taken every morning for 14 days.
Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37.
Two tablets to be taken every morning for 14 days.
|
Experimental: Placebo or Saracatinib (Cross-over)
The groups will now cross over i.e. the group that had the study drug in the first arm will get the placebo in the second arm and the group that had the placebo in the first arm will have the study drug in the second arm.
|
AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49.
Two tablets to be taken every morning for 14 days.
Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37.
Two tablets to be taken every morning for 14 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference between study drug and placebo in BOLD activity in the ventral visual stream during visual recognition vs. the control task measure using fMRI
Time Frame: 2 months (two treatment arms)
|
Using functional magnetic resonance imaging (fMRI) to look at the effect of saracatinib in attenuating the reduced response in the ventral visual stream on the visual recognition tasks, compared to placebo.
|
2 months (two treatment arms)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference between study drug and placebo in BOLD activity in the occipito-temporal region during the visual processing task (Kanisza illusion)
Time Frame: 2 months (two treatment arms)
|
Using functional magnetic resonance imaging (fMRI) to look at the difference in blood oxygen level dependent activity in the occipito-temporal regions between Saracatinib and placebo during a visual processing task that involves looking and making decisions about a visual illusion that involves shapes that create the illusion of edges that do not exist physically
|
2 months (two treatment arms)
|
Change in Mismatch negativity (MMN) in microvolts (mV) and connectivity with the posterior cingulate hub of the default mode network
Time Frame: 2 months (two treatment arms)
|
Using electroencephalogram (EEG) to look at change in brain activity within specific areas of the brain that are known to work together.
|
2 months (two treatment arms)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seed-based connectivity from the Regions of Interest (ROI) within the inferotemporal cortex.
Time Frame: 2 months (two treatment arms)
|
Using fMRI to look at connectivity within the inferotemporal cortex.
|
2 months (two treatment arms)
|
Difference between study drug and placebo in MMN amplitude at FZ on EEG.
Time Frame: 2 months (two treatment arms)
|
2 months (two treatment arms)
|
|
Test a prediction error model for the effects of Saracatinib on brain activity during a mismatch negativity paradigm on the EEG.
Time Frame: 2 months (two treatment arms)
|
2 months (two treatment arms)
|
|
Difference between study drug and placebo in Factor summary score on the scales for assessment of positive symptoms in Parkinson's disease (SAPS-PD) and the Neuropsychiatric Inventory (NPI).
Time Frame: 2 months (two treatment arms)
|
Scale for the Assessment of Positive Symptoms- Parkinson's Disease (SAPS-PD)- a 9 question scale that asks about the most frequently reported non-motor symptoms of Parkinson's disease including visual hallucinations and delusions and the severity of symptoms. Neuropsychiatric Inventory (NPI)- an informant-based scale that was developed to assess neuropsychiatric symptoms. It consists of 12 items, but section A and B are delusions and hallucinations respectively. If symptoms are present, then more information is obtained through questions about frequency (scale of 1-3) and severity (scale of 1-4). The total scores are added up to get the NPI total score. |
2 months (two treatment arms)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mitul Mehta, King's College London
Publications and helpful links
General Publications
- Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, Kaufman AC, Rosenberg BJ, Sekine-Konno T, Varma P, Chen K, Koleske AJ, Reiman EM, Strittmatter SM, van Dyck CH. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. Alzheimers Res Ther. 2015 Apr 14;7(1):35. doi: 10.1186/s13195-015-0119-0. eCollection 2015.
- Chang A, Fox SH. Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management. Drugs. 2016 Jul;76(11):1093-118. doi: 10.1007/s40265-016-0600-5. Erratum In: Drugs. 2016 Sep;76(13):1319. Dosage error in article text.
- Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017 Feb;13(2):81-95. doi: 10.1038/nrneurol.2016.200. Epub 2017 Jan 20.
- Byock I. Taking Psychedelics Seriously. J Palliat Med. 2018 Apr;21(4):417-421. doi: 10.1089/jpm.2017.0684. Epub 2018 Jan 22.
- Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. Psilocybin impairs high-level but not low-level motion perception. Neuroreport. 2004 Aug 26;15(12):1947-51. doi: 10.1097/00001756-200408260-00023.
- Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van Laar T. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain. 2009 Nov;132(Pt 11):2980-93. doi: 10.1093/brain/awp223. Epub 2009 Sep 15.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Schizophrenia Spectrum and Other Psychotic Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Psychotic Disorders
- Parkinson Disease
- Mental Disorders
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Saracatinib
Other Study ID Numbers
- 247303
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease Psychosis
-
SunovionCompletedParkinson Disease PsychosisUnited States
-
ACADIA Pharmaceuticals Inc.CompletedParkinson Disease PsychosisUnited States
-
ACADIA Pharmaceuticals Inc.TerminatedParkinson Disease PsychosisUnited States
-
Vanda PharmaceuticalsWithdrawnParkinson Disease PsychosisUnited States
-
Johns Hopkins UniversityAgeneBioRecruitingParkinson Disease PsychosisUnited States
-
Vanderbilt University Medical CenterACADIA Pharmaceuticals Inc.RecruitingParkinson Disease | Neurodegenerative Diseases | Parkinson Disease PsychosisUnited States
-
Olaf BlankeUniversity Hospital, Geneva; University Hospital Inselspital, Berne; Centre Hospitalier... and other collaboratorsUnknown
-
Tasly Pharmaceutical Group Co., LtdRecruitingParkinson's Disease PsychosisChina
-
VA Office of Research and DevelopmentRecruitingParkinson's Disease PsychosisUnited States
-
ACADIA Pharmaceuticals Inc.CompletedParkinson's Disease PsychosisFrance, United States, Bulgaria, Russian Federation, United Kingdom, Ukraine, India
Clinical Trials on Saracatinib
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
National Cancer Institute (NCI)TerminatedInvasive Thymoma and Thymic Carcinoma | Recurrent Thymoma and Thymic Carcinoma | Stage III Thymoma | Stage IVA Thymoma | Stage IVB ThymomaUnited States
-
National Cancer Institute (NCI)CompletedTongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Stage III Gastric Cancer | Adenocarcinoma of the Stomach | Stage IV Esophageal Cancer | Stage III Esophageal CancerCanada, United States
-
National Cancer Institute (NCI)CompletedLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Malignant Pleural EffusionUnited States
-
Baylor College of MedicineUniversity of South Florida; National Institutes of Health (NIH); Brigham and... and other collaboratorsTerminatedPulmonary LymphangioleiomyomatosisUnited States
-
National Cancer Institute (NCI)CompletedStage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerCanada
-
Stephen M. StrittmatterNational Institute of Neurological Disorders and Stroke (NINDS)CompletedAlzheimer's DiseaseUnited States
-
National Cancer Institute (NCI)CompletedUterine Carcinosarcoma | Endometrial Stromal Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Uterine Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage IV Uterine Sarcoma | Dermatofibrosarcoma Protuberans | Adult Rhabdomyosarcoma and other conditionsCanada, United States
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Hormone-resistant Prostate CancerUnited States